Clinical meetings

← vista completa

Published on December 1, 2009 | http://doi.org/10.5867/medwave.2009.12.4305

Prevention of chronic kidney disease: practical measures

Prevención de la enfermedad renal crónica II: medidas específicas

Miriam Alvo Abodovsky

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Miriam Alvo Abodovsky

Hospital Clínico Universidad de Chile, Santiago, Chile

Figures

Article has no figures.

Forum

No messages

History

Citation Alvo Abodovsky M. Prevention of chronic kidney disease: practical measures. Medwave 2009;9(12):e4305 doi: 10.5867/medwave.2009.12.4305

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/12/2009

Index

Metrics

Not available at the moment.

Notes

References

  1. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983 May 28;1(8335):1175-9. | CrossRef | PubMed
  2. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG,et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995 Nov 15;123(10):754-62. | PubMed
  3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456-62. | CrossRef | PubMed
  4. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004 Nov 4;351(19):1941-51. Epub 2004 Oct 31. | CrossRef | PubMed
  5. Parving et al. Effects of Losartan Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9. | CrossRef | PubMed
  6. Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 2003 Mar;63(3):1094-103. | CrossRef | PubMed
  7. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003 Jan 11;361(9352):117-24. | CrossRef | PubMed
  8. Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med. 2008 Jun 5;358(23):2503-5. | CrossRef | PubMed
  9. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006 Jan 12;354(2):131-40. | CrossRef | PubMed
  10. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009 Jul 2;361(1):40-51. | CrossRef | PubMed
  11. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006 Nov;119(11):912-9. | CrossRef | PubMed
  12. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003 May;63(5):1791-800. | CrossRef | PubMed
  13. Terada Y, Kobayashi T, Kuwana H, Tanaka H, Inoshita S, Kuwahara M, et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol. 2005 Aug;16(8):2296-305. Epub 2005 Jun 23. | CrossRef | PubMed
  14. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006 Jun;47(6):1084-93. Epub 2006 Apr 24. | PubMed
  15. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol. 2005 Nov;16(11):3306-14. Epub 2005 Sep 28. | PubMed
  16. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens. 2003 Sep;16(9 Pt 1):781-8. | CrossRef | PubMed
  17. van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens. 2006 Nov;24(11):2285-92. | CrossRef | PubMed
  18. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006 Dec;70(12):2116-23. Epub 2006 Oct 11. | PubMed
  19. Campese VM, Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int. 2007 Jun;71(12):1215-22. Epub 2007 May 9. | CrossRef | PubMed
  20. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001 Jan;59(1):260-9. | CrossRef | PubMed
  21. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993 Sep 30;329(14):977-86. | CrossRef | PubMed